Japan
· Delayed Price · Currency is JPY Kringle Pharma Statistics
Total Valuation
Kringle Pharma has a market cap or net worth of JPY 5.87 billion. The enterprise value is 3.99 billion.
| Market Cap | 5.87B |
| Enterprise Value | 3.99B |
Important Dates
The last earnings date was Monday, May 12, 2025.
| Earnings Date | May 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Kringle Pharma has 6.84 million shares outstanding. The number of shares has increased by 17.90% in one year.
| Current Share Class | 6.84M |
| Shares Outstanding | 6.84M |
| Shares Change (YoY) | +17.90% |
| Shares Change (QoQ) | +0.26% |
| Owned by Insiders (%) | 6.80% |
| Owned by Institutions (%) | 9.69% |
| Float | 5.47M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 81.57 |
| PB Ratio | 3.65 |
| P/TBV Ratio | 3.65 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -4.42 |
| EV / Sales | 55.37 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 14.61
| Current Ratio | 14.61 |
| Quick Ratio | 12.38 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -45.90% and return on invested capital (ROIC) is -30.63%.
| Return on Equity (ROE) | -45.90% |
| Return on Assets (ROA) | -23.14% |
| Return on Invested Capital (ROIC) | -30.63% |
| Return on Capital Employed (ROCE) | -45.11% |
| Revenue Per Employee | 4.80M |
| Profits Per Employee | -60.13M |
| Employee Count | 15 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +18.48% in the last 52 weeks. The beta is 0.34, so Kringle Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.34 |
| 52-Week Price Change | +18.48% |
| 50-Day Moving Average | 836.36 |
| 200-Day Moving Average | 869.31 |
| Relative Strength Index (RSI) | 50.93 |
| Average Volume (20 Days) | 58,065 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Kringle Pharma had revenue of JPY 72.00 million and -902.00 million in losses. Loss per share was -133.28.
| Revenue | 72.00M |
| Gross Profit | 72.00M |
| Operating Income | -963.00M |
| Pretax Income | -901.00M |
| Net Income | -902.00M |
| EBITDA | n/a |
| EBIT | -963.00M |
| Loss Per Share | -133.28 |
Balance Sheet
The company has 1.89 billion in cash and n/a in debt, giving a net cash position of 1.89 billion or 275.85 per share.
| Cash & Cash Equivalents | 1.89B |
| Total Debt | n/a |
| Net Cash | 1.89B |
| Net Cash Per Share | 275.85 |
| Equity (Book Value) | 1.61B |
| Book Value Per Share | 235.19 |
| Working Capital | 2.11B |
Cash Flow
| Operating Cash Flow | -750.00M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -1,337.50% |
| Pretax Margin | -1,251.39% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Kringle Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -17.90% |
| Shareholder Yield | n/a |
| Earnings Yield | -15.36% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Kringle Pharma has an Altman Z-Score of 3.98.
| Altman Z-Score | 3.98 |
| Piotroski F-Score | n/a |